Up until recently, the stock has been a chronic underperformer.

Pfizer (PFE) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term. Shares of this ...

Pfizer Inc. Q4 shows post-COVID growth, Seagen-fueled oncology gains, and obesity upside. Click for this updated look at PFE ...

Healthcare dividend stocks are selling off with the turbulence in the Middle East. But, why? The best plays here are ...

Is PFE a good stock to buy now? We came across a bullish thesis on Pfizer Inc. on Investomine’s Substack. In this article, we ...

In the closing of the recent trading day, Pfizer (PFE) stood at $26.97, denoting a -1.61% move from the preceding trading day ...

Pfizer Inc. (NYSE:PFE) is one of Jim Cramer’s latest stock calls as he discussed the bullish AI investment thesis amid the ...

Pfizer expands oncology and immunology pipeline strength New therapies show progress in clinical development Focus shifts ...

The trial tests two oral forms of tafamidis, a key Pfizer drug for transthyretin amyloidosis (ATTR-PN). One is the existing 61 mg free acid capsule and the other is a new 61 mg free acid tablet, both ...

Pharma/biotech giants Pfizer PFE and Bristol Myers BMY boast a dominant position in the lucrative oncology space. Oncology or ...